20B: Biomark Diagnostics Inc. - Summary | Jitta

Biomark Diagnostics Inc.

DEU:20B

Price
€0.34
Loss Chance
57.9%
1.58JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
497 / 546
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (19)
Financial Strength (43)
Return to Shareholders (0)
Competitive Advantage (16)
Jitta Signs
Operating MarginDeclined
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.58
100.00%
2.41
> 1,000%
2.41
> 1,000%
2.17
21.92%
0.65
100.00%
3.41
> 1,000%
COMPANY DESCRIPTION
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.